Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:83-89
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gustafsson, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gustafsson, I.

Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction

Ida Gustafsson, MDa, Christian Torp-Pedersen, MD, PhD, FACC*, Lars Køber, MD*, Finn Gustafsson, MDa, Per Hildebrandt, MD, PhDa on behalf of the Trace Study Group

a Department of Cardiology and Endocrinology, Frederiksberg University Hospital, Frederiksberg, Denmark
* Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark



View larger version (10K):

[in a new window]
 
Figure 1 Cumulative mortality from all causes for patients with (A) and without (B) diabetes receiving trandolapril or placebo.

 


View larger version (11K):

[in a new window]
 
Figure 2 Rate of progression to severe or resistant heart failure for patients with (A) and without (B) diabetes receiving trandolapril or placebo.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement